Long-term serological evaluation of patients with cystic echinococcosis treated with benzimidazole carbamates.
Seeking better immunological markers indicating the long-term outcome of cystic echinococcosis (CE) after chemotherapy we studied 23 patients receiving albendazole, clinically followed for 8 years, and grouped ultrasonographically according to therapeutic outcome. Antibody responses against a partially purified fraction of hydatid fluid (HFF) and antigen B (AgB) were evaluated by indirect haemagglutination (IHA), ELISA and immunoblotting (IB). Although IHA titres varied over the course of treatment, differences in mean antibody titres to HFF between groups were significant only at 4 years (P = 0.031). IgG isotype expression remained unchanged during follow-up whereas IgE expression decreased in patients with cured or stable disease. AgB disclosed higher IgG4 expression (P < 10(-4); P = 0.025) and lower IgG1 expression than HFF (P < 10(-4); P = 0.022). IHA antibody titres were higher in patients with progressive than in those with cured or stable disease, even in those with the same cyst type. ELISA isotype profiles differed between groups, particularly for type CE 3, 4 and 5 cysts: higher serum IgG1 and IgG3, lower IgG4 and IgE in patients with cured or stable disease. Although combined serological testing provides scarce information on the long-term outcome of CE after chemotherapy it may be useful for reviewing in a retrospective study the outcome of a cyst and for assessing the host-parasite relationship.
Riganò
R
R
Department of Immunology, Istituto Superiore di Sanità, Rome, Italy.
Ioppolo
S
S
Ortona
E
E
Margutti
P
P
Profumo
E
E
Ali
M D
MD
Di Vico
B
B
Teggi
A
A
Siracusano
A
A
D000328:Adult; D000368:Aged; D015766:Albendazole / Q000627:therapeutic use*; D000818:Animals; D000909:Antibodies, Helminth / Q000097:blood*; D000923:Anticestodal Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D003560:Cysts / Q000145:classification; D018450:Disease Progression; D004443:Echinococcosis / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy*; D004446:Echinococcus / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D006386:Hemagglutination Tests; D006801:Humans; D015151:Immunoblotting; D008875:Middle Aged; D016896:Treatment Outcome
D000909:Antibodies, Helminth; D000923:Anticestodal Agents; D015415:Biomarkers; D015766:Albendazole